Li Ronghui, Luo Panpan, Guo Yuge, He Yang, Wang Chunjiang
Department of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan, China.
College of pharmacy, Changsha Medical University, Changsha, Hunan, China.
Expert Opin Drug Saf. 2024 Sep 4:1-5. doi: 10.1080/14740338.2024.2396387.
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have recently been linked to be associated with acute pancreatitis (AP), but the clinical characteristics are unclear. This study investigated the clinical characteristics of SGLT-2i and AP and provided reference for the prevention and treatment of AP.
Case reports, case series, and clinical studies of SGLT2i induced AP were collected by retrieving Chinese and English data from the database until 31 December 2023.
Twenty-one patients were included, with a median age of 50.5 years (range 26,73). SGLT-2i were mainly involved in empagliflozin (13 cases, 61.9%), canagliflozin (4 cases, 19%) and dapagliflozin (4 cases, 19%). The median time from initial administration to the onset of AP was 21 days (range 1, 120). Abdominal pain (21 cases, 100%) was the most commonly complained symptom. The median lipase value was 388 U/L (range 36, 10000), and the median amylase value was 535 U/L (range 26, 3765). Twenty-one patients recovered completely after stopping the drug and receiving conservative treatment.
SGLT-2i are associated with AP. Given the rising prescription of SGLT-2i, physicians should consider these agents as a potential cause of pancreatitis after excluding other etiologies.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）最近被认为与急性胰腺炎（AP）有关，但临床特征尚不清楚。本研究调查了SGLT-2i与AP的临床特征，为AP的防治提供参考。
通过检索数据库中的中英文资料，收集截至2023年12月31日SGLT2i诱导AP的病例报告、病例系列和临床研究。
纳入21例患者，中位年龄50.5岁（范围26,73）。SGLT-2i主要涉及恩格列净（13例，61.9%）、卡格列净（4例，19%）和达格列净（4例，19%）。从首次给药到AP发作的中位时间为21天（范围1,120）。腹痛（21例，100%）是最常见的主诉症状。脂肪酶中位值为388 U/L（范围36,10000），淀粉酶中位值为535 U/L（范围26,3765）。21例患者停药并接受保守治疗后完全康复。
SGLT-2i与AP有关。鉴于SGLT-2i的处方量不断增加，医生在排除其他病因后应将这些药物视为胰腺炎的潜在病因。
